Effects of yellow fever vaccination

Adhiyaman, Vedamurthy; Oke, Anuoluwapo R; Cefai, C

doi:10.1016/s0140-6736(01)06914-8

Cited by 37 publications

(6 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since then, two additional unpublished cases of YEL-AVD and one report of YEL-AND have been identified and reported to the Vaccine Adverse Event Reporting System (VAERS). Similar serious adverse events in persons vaccinated with YEL were described in three additional YEL-AVD case reports from Europe [8][9][10]. Deaths from YEL-AVD have been reported in Brazil [11] and Australia [12].…”

Section: Introductionsupporting

confidence: 70%

Yellow fever vaccine: An updated assessment of advanced age as a risk factor for serious adverse events

Khromava

Eidex

Weld

et al. 2005

Vaccine

197

136

View full text Add to dashboard Cite

Chen, Robert T.; and Cetron, Martin S., "Yellow fever vaccine: An updated assessment of advanced age as a risk factor for serious adverse events" (2005 AbstractSince 1996, the scientific community has become aware of 14 reports of yellow fever vaccine (YEL)-associated viscerotropic disease (YEL-AVD) cases and four reports of YEL-associated neurotropic disease (YEL-AND) worldwide, changing our understanding of the risks of the vaccine. Based on 722 adverse event reports after YEL submitted to the U.S. Vaccine Adverse Event Reporting System in 1990-2002, we updated the estimates of the age-adjusted reporting rates of serious adverse events, YEL-AVD and YEL-AND. We found that the reporting rates of serious adverse events were significantly higher among vaccinees aged ≥60 years than among those 19-29 years of age (reporting rate ratio = 5.9, 95% CI 1.6-22.2). Yellow fever is a serious and potentially fatal disease. For elderly travelers, the risk for severe illness and death due to yellow fever infection should be balanced against the risk of a serious adverse event due to YEL.

show abstract

Section: Introductionsupporting

confidence: 70%

Yellow fever vaccine: An updated assessment of advanced age as a risk factor for serious adverse events

Khromava

Eidex

Weld

et al. 2005

Vaccine

197

136

View full text Add to dashboard Cite

show abstract

“…It is notable that several reports of YF-AVD have occurred among females under 30 years of age [23][24][25][26]. In fact, of the 27 YF-AVD published cases identified worldwide (with age and sex data), 75% of cases under age 40 were female, compared to 11% of cases ≥40 years [10,[23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39]. In the data analyzed in this study, however, the risk of SAEs was higher for males than females in all age groups.…”

Section: Discussionmentioning

confidence: 99%

Adverse event reports following yellow fever vaccination

Lindsey

Schroeder

Miller

et al. 2008

Vaccine

234

159

View full text Add to dashboard Cite

Yellow fever (YF) vaccine has been used for prevention of YF since 1937 with over 500 million doses administered. However, rare reports of severe adverse events following vaccination have raised concerns about the vaccine's safety. We reviewed reports of adverse events following YF vaccination reported to the U.S. Vaccine Adverse Event Reporting System (VAERS) from 2000 to 2006. We used estimates of age and sex distribution of administered doses obtained from a 2006 survey of authorized vaccine providers to calculate age- and sex-specific reporting rates of all serious adverse events (SAE), anaphylaxis, YF vaccine-associated neurotropic disease, and YF vaccine-associated viscerotropic disease. Reporting rates of SAEs were substantially higher in males and in persons aged > or =60 years. These findings reinforce the generally acceptable safety profile of YF vaccine, but highlight the importance of physician and traveler education regarding the risks and benefits of YF vaccination, particularly for travelers > or =60 years of age. Vaccination should be limited to persons traveling to areas where the risk of YF is expected to exceed the risk of serious adverse events after vaccination, or if not medically contraindicated, where national regulations require proof of vaccination to prevent introduction of YF.

show abstract

“…These cases occurred during 1996-2001 and described patients with severe multiple organ system failure; 6 of the 7 patients died (31,(34)(35)(36). Subsequently, retrospective and prospective case finding has identified three additional suspected cases (37)(38)(39). These additional cases demonstrate that this serious adverse reaction probably occurs as a clinical spectrum of disease severity, from moderate illness with focal organ dysfunction to severe disease with overt multiple organ system failure and death.…”

Section: Yellow Fever Vaccine-associated Viscerotropic Diseasementioning

confidence: 95%